Clinical trials: Stage III Non-small Cell Lung Cancer
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Non Small Cell Lung Cancer
Performance Status During Treatment With Pemetrexed in Patients With NSCLC
The primary research objective of this observational study in pretreated patients with NSCLC of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second cycle of second-line treatment with single…
- Trial name
- PERFORMANCE (NCT00540241)
- Testing
- Pemetrexed
- Where
- Germany
- Volunteers
- 542 people
- Sponsor
- Eli Lilly and Company
Non-small-cell Lung Cancer
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
This study will evaluate the efficacy and safety of QL1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT05329025
- Testing
- QL1706
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objectives of the study are: To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell…
- Conditions
- Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT03088540
- Testing
- Pemetrexed, Paclitaxel, Gemcitabine
- Where
- 192 sites in Australia, Belarus and 22 more
- Volunteers
- 712 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this clinical trial is to compare Utidelone with Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously failed platinum-containing chemotherapy regimens.
- Trial name
- NCT05673590
- Testing
- Utidelone Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
The vaccine contains humanized recombinant antigen (Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation.
- Trial name
- NSCLC (NCT01444118)
- Testing
- Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
- Where
- United Kingdom
- Sponsor
- Bioven Europe
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
- Trial name
- NCT00130728
- Testing
- bevacizumab, erlotinib HCl
- Where
- 4 sites in United States
- Volunteers
- 636 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy.
- Trial name
- NCT02013206
- Testing
- erlotinib [Tarceva]
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Muscle Wasting, Non-Small Cell Lung Cancer
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
- Trial name
- NCT01355497
- Testing
- GTx-024
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- GTx
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-small-cell Lung
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care.
- Trial name
- NCT00036647
- Testing
- Tarceva (erlotinib HCl, OSI-774 )
- Where
- 97 sites in United States, Argentina and 15 more
- Volunteers
- 731 people
- Sponsor
- OSI Pharmaceuticals
Non Squamous Non-small Cell Lung Cancer
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
This study is a randomized, controlled, double-blind, multicenter Phase III registration clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (pemetrexed plus carboplatin/cisplatin)…
- Trial name
- NCT07383116
- Testing
- Pemetrexed injection, Carboplatin Injection, Cisplatin injection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
This study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC.
- Trial name
- SYNSTAR-02 (NCT07376382)
- Testing
- SYS6010, Osimertinib, platinum-pemetrexed
- Volunteers
- 680 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company